Detailed Narrative
Strategic Shift and Non-GPL Business Growth
Alivus Life Sciences has successfully strengthened its business over the past two years, significantly reducing its dependence on the GPL business. The non-GPL segment's contribution to the overall business increased from 59% in FY22 to 71% in FY26, demonstrating a robust 13% year-on-year growth. This diversification, supported by strong demand in regulated markets and new product launches, is a key driver for the company's sustainable growth trajectory.
Record Profitability and Margin Expansion
The company achieved its highest-ever EBITDA margin of 33.6% in FY26, expanding by 360 basis points year-on-year. This significant improvement was attributed to a favorable product mix, disciplined cost management, and enhanced operational efficiencies, even without the benefit of PLI. Over the last two years (FY24-FY26), Alivus added INR270 crores in incremental revenue and INR220 crores in EBITDA, with EBITDA CAGR at 15.8%.
Aggressive Capacity Expansion and R&D Investment
Alivus is making substantial investments in capacity expansion and R&D for future growth. The company spent INR306 crores on capex in FY26 and plans to incur INR540 crores in FY27, entirely funded through internal accruals. These investments are directed towards building new capabilities at the greenfield Solapur project and strengthening the R&D platform. The goal is to expand API capacity from 1,198 KL in FY24 to a planned 2,690 KL by FY28.
Operational Efficiency and Cost Control
The company has focused on improving operational efficiency and implementing better cost processes. A notable initiative includes shifting from gas to briquette boilers, which helps stabilize operational costs and mitigate the impact of rising energy prices. This strategic move, combined with disciplined cost management, has been instrumental in driving the significant expansion of gross margins to 58.2% for FY26.
Robust Pipeline and High Potency API Development
Alivus maintains a strong pipeline with over 611 DMF and CEP filings globally. The high-potent API portfolio is a key focus, with 28 products in the pipeline, 12 of which are validated and 7 in advanced stages. While significant revenue from HPAPIs is anticipated post-2028 due to patent expiries, the company is actively investing in areas like flow chemistry and complex molecules to ensure long-term growth and differentiation.
Strong Cash Generation and Net Debt-Free Status
The company has demonstrated robust cash generation, accumulating INR984 crores from operations over the past two years. After allocating INR472 crores for capex and INR61 crores for dividends, Alivus maintains a 'war chest' of INR451 crores. As of March 31, 2026, cash and cash equivalents stood at INR782 crores, reinforcing its net debt-free position and providing financial flexibility for future growth initiatives.
CDMO Business Recovery and Future Outlook
The CDMO business experienced a meaningful recovery starting from Q3 FY26, driven by traction in existing projects and the scaling up of newer ones. Management expects this positive momentum to continue and aims to close two new CDMO deals in the early second half of FY27. This segment, with its inherently better margins, is a crucial component of the company's strategy to enhance overall profitability.
Diversified Geographical Presence
Alivus has a well-diversified geographical footprint, with significant contributions from mature markets such as India, Europe, Latin America, and the U.S. The company has also successfully expanded into newer geographies like Japan over the last 4-5 years, which is now growing well. This broad market presence, coupled with a strategy to select molecules suitable for various regions, ensures balanced growth across its portfolio.